FDA Grants Mustang Bio MB-102 Orphan Drug for Acute Myeloid Leukemia
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Mustang Bio(http:// announcedthat the U.SFood andDrug(http://Administration (
FDA(http://) has granted MB-102 (CD123 CAR T) the eligibility for orphan drugs (ODD) for the treatment of acute myeloid leukemia (AML)Previously, the FDA also granted MB-102 the orphan drug for the treatment of parent-cell plasma-like dendritic cell tumors (BPDCN)MB-102 (CD123 CAR T) is a CAR T-cell therapy that engineers patient T-cells to identify and eliminate tumors that express CD123CD123 is widely expressed in bone marrow cells in patients with bone marrow hyperplasia syndrome and hematoma malignancies, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), hair cell leukemia (HCL), BPDCN, chronic myeloid leukemia (CML), and Golden Hodge lymphoma (HL)In the first human clinicaltrial(http://City Hope (NCT02159495), MB-102 showed complete remission when treating AML and BPDCN at low doses, with no dose-restricted toxicityCurrently, the dose increase of two indications in this study is under way
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
